secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-022580
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 1.02, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma enters $100M ELOC with Arena, terminates prior ELOC
--------------------------------------------------------------------

- Entered into $100M equity line of credit (ELOC) with Arena Business Solutions, effective Nov 11, 2025.
- Prior $100M ELOC with Arena dated Feb 13, 2025 mutually terminated on same day.
- Company may sell shares at 96% of VWAP; maximum advance amount varies by time of notice (up to $20M).
- Issued transaction fee shares and paid $40,000 in fees (cash and shares) to Arena.
- ELOC term is 36 months; subject to ownership limitation of 9.99% and Nasdaq exchange cap until shareholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225022580/0001493152-25-022580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225022580/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer